SCHEMBL3472408

SCHEMBL3472408

COc1cc(NC(=O)c2ccc(-c3cc(C(F)(F)F)nn3-c3ccccc3Cl)cc2)cc(OC)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
POLB P06746 3/20 0.56
THRB P10828 2/20 0.54
RXRA P19793 2/20 0.52
NR1H2 P55055 2/20 0.52
NR1H3 Q13133 2/20 0.52
TP53 P04637 3/20 0.50
NPC1 O15118 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47
SLC16A3 O15427 2/20 0.47
SLC16A1 P53985 2/20 0.47
PTGS2 P35354 4/20 0.47
PTGS1 P23219 3/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
TSHR P16473 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3473656 0.93 MAPT (0.64) MAPTSMN1; SMN2POLBTHRBRXRA
SCHEMBL3471008 0.93 MAPT (0.64) MAPTSMN1; SMN2POLBTHRBRXRA
SCHEMBL3471509 0.89 MAPT (0.67) MAPTSMN1; SMN2POLBTHRBRXRA
SCHEMBL3473594 0.89 MAPT (0.55) MAPTSMN1; SMN2POLBTHRBRXRA
SCHEMBL3472874 0.88 MAPT (0.56) MAPTSMN1; SMN2POLBTHRBRXRA
SCHEMBL3471324 0.88 MAPT (0.59) MAPTSMN1; SMN2POLBTHRBRXRA
SCHEMBL3471865 0.88 MAPT (0.69) MAPTSMN1; SMN2POLBTHRBRXRA
SCHEMBL3471035 0.88 MAPT (0.64) MAPTSMN1; SMN2POLBTHRBRXRA
SCHEMBL3473226 0.87 MAPT (0.56) MAPTSMN1; SMN2POLBTHRBRXRA
SCHEMBL3474139 0.87 MAPT (0.56) MAPTSMN1; SMN2POLBTHRBRXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 MAPT 4737/4885SMN1; SMN2 4666/4885POLB 3735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.